Twist Bioscience Corporation (TWST) Stock Analysis
Healthcare · Diagnostics & Research
Sell if holding. Engine safety override at $70.04: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: High short interest: 34%; Below-average business quality; Rich valuation.
Twist Bioscience manufactures synthetic DNA and NGS tools using a proprietary silicon chip-based synthesis platform, serving 3,800+ customers in healthcare ($215.1M), chemicals/materials ($93.2M), academic research ($65.9M), and food/agriculture markets. FY2025 revenue was... Read more
Sell if holding. Engine safety override at $70.04: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: High short interest: 34%; Below-average business quality; Rich valuation. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.5/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 55d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent developments
updated 2026-06-09Recent Developments — Twist Bioscience Corporation
Latest news
- NEWS LenioBio GmbH Partners With Twist Bioscience To Integrate Its ALiCE Platform With Twist's DNA Production, Automation Too — benzinga May 8, 2026 positive
- NEWS These Analysts Boost Their Forecasts On Twist Bioscience After Q2 Results — benzinga May 5, 2026 positive
- NEWS This UFP Industries Analyst Turns Bullish; Here Are Top 4 Upgrades For Tuesday — benzinga May 5, 2026 positive
- NEWS Crowdstrike To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday — benzinga May 5, 2026 positive
- NEWS Leerink Partners Upgrades Twist Bioscience to Outperform, Announces $70 Price Target — benzinga May 5, 2026 positive
Generated 2026-06-09T22:21:41Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSuppliersingle-source supplier for critical DNA synthesis component10-K Item 1A: 'We depend on one single-source supplier for a critical component for our DNA synthesis process.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Unprofitable operations — net margin -19.8%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $70.04: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: High short interest: 34%; Below-average business quality; Rich valuation. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $65.14. Score 4.5/10, moderate confidence.
Take-profit target: $78.89 (+12.6% upside). Prior stop was $65.14. Stop-loss: $65.14.
Concentration risk — Supplier: single-source supplier for critical DNA synthesis component; Target reached (-20.0% upside); Quality below floor (3.3 < 4.0).
Twist Bioscience Corporation trades at a P/E of N/A (forward -34.2). TrendMatrix value score: 3.0/10. Verdict: Sell.
15 analysts cover TWST with a consensus score of 4.5/5. Average price target: $64.
What does Twist Bioscience Corporation do?Twist Bioscience manufactures synthetic DNA and NGS tools using a proprietary silicon chip-based synthesis platform,...
Twist Bioscience manufactures synthetic DNA and NGS tools using a proprietary silicon chip-based synthesis platform, serving 3,800+ customers in healthcare ($215.1M), chemicals/materials ($93.2M), academic research ($65.9M), and food/agriculture markets. FY2025 revenue was $376.6M across synthetic biology tools, NGS kits, and biopharma antibody discovery services.